Skip to main content
logo
HomeUS StocksKRYS

K

Krystal Biotech

$ 311.95

-3.87 (-1.23%)loss
as on 21 Nov 2026 at 01:23 AM IST
analyst100% Buy
Overview
News
History
Fundamentals
Investment Returns
Financials
Balance Sheet
Cash Flow
Peers

Krystal Biotech Share Price Today

Krystal Biotech (KRYS) share price is $311.95 on the NASDAQ as of November 21, 2026 at 01:23 AM IST, down 1.23% ($3.87) from its previous close of $315.82. In rupee terms, one share is worth about ₹28,948.59 at today's USD/INR rate of 92.80. In today's trading session KRYS reached a high of $321.27 and low of $310.94.

Stock Overview

  • Symbol : KRYS
  • Open : $313.38
  • Previous Close : $315.82
  • Day's Range : $310.94 – $321.27
  • 52-Week Range : $203.17 – $382.54
  • Price in INR : ₹28,948.59 (USD/INR: 92.80)

KRYS Stock Performance ($)

Markets Today

High

321.27

Low

310.94

Open at

313.38

Prev Close

315.82

Volumes

1,44,456

Price Movement

310.94321.27
0.32%Loss
down side
up side
2.90%Profit

Historical Performance

3 M High

373.31

3 M Low

281.40

1 Yr High

382.54

1 Yr Low

203.17

3 Yr High

382.54

3 Yr Low

99.00

5 Yr High

382.54

5 Yr Low

38.86

1-Year Performance

203.17382.54
53.54%Loss
down side
up side
18.45%Profit

KRYS Analyst Rating

Buy

Analysts have suggested that investors can Buy this Stock

- By ViewTrade from 6 analysts

Buy

100%

Hold

0%

Sell

0%

KRYS Latest News



KRYS Share Price History ($)

Close Price

Volume

KRYS share price in last 10 trading sessions

DayOpenCloseChange%Day HighDay LowVolume
19 Nov 2026315.34316.06
0.23% profit
322.02311.022,25,438
18 Nov 2026297.60315.09
5.88% profit
316.86297.602,21,771
17 Nov 2026299.00298.64
-0.12% Loss
299.88295.0684,013
16 Nov 2026302.86297.67
-1.71% Loss
306.44295.011,16,474
13 Nov 2026305.68305.13
-0.18% Loss
306.73300.3976,199
12 Nov 2026307.72305.90
-0.59% Loss
309.68304.061,07,766
11 Nov 2026308.09308.99
0.29% profit
311.05303.591,21,243
10 Nov 2026302.60306.43
1.27% profit
307.48300.861,31,916
09 Nov 2026302.65302.99
0.11% profit
310.66297.522,16,405
06 Nov 2026298.31300.61
0.77% profit
305.60297.521,60,740

KRYS Fundamentals

Company Valuation

Market Cap

$9,243.90M

PE Ratio

41.44

PEG Ratio

4.01

PB Ratio

6.30

ROE

19.22%

ROCE

14.99%

KRYSTAL BIOTECH INC Return Calculator

You have invested
Investment Period

Current value of ₹10,000 invested 5 years ago, as on today

₹ 0

Gain

₹ 10,000 (495.66%)

Note: Past profits do not guarantee future returns.

KRYS Investment Returns

1 Week

1 Month

3 Months

6 Months

KRYS Financials Summary

Revenue
EBITDA
Net Profit
EPS
Revenue

($ Mn)

Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
98107116119127

KRYS Financials

Income Statement

($ Mn)

Quarterly StatementSep 2025Dec 2025Mar 2026Jun 2026Sep 2026
98107116119127
Expenses5663636156
Operating Profit4144545871
Operating Profit Margin %42%41%46%49%56%
Other Income00000
4346545871
Interest77889
Depreciation22000
4851616680
Tax %65%1%9%17%21%
Net Profit7951565563
EPS32222

Balance Sheet

($ Mn)

Yearly Balance SheetJun 2025Sep 2025Mar 2026Jun 2026Sep 2026
1,1381,2401,3971,5011,586
Fixed Assets158156161161159
Current Assets8419261,0201,0601,122
Capital Work in Progress158156161161159
Investments467472516675731
Other Assets00000
1,1381,2401,3971,5011,586
Current Liabilities8791108127142
Non Current Liabilities111112148
1,0411,1381,2771,3591,436
Reserve & Surplus-105-2678131189
Share Capital1,1461,1641,1981,2291,247

Cash Flow

($ Mn)

Quarterly Cash FlowSep 2025Dec 2025Mar 2026Jun 2026Sep 2026
Cash from Operating4078807591
Cash from Investing-411-64-162-58
Cash from Financing416-10153
Net Cash Flow391046-7237

KRYS Revenue Growth

All values are ($ Mn)

Revenue

Profit

Loss

Financial YearRevenueRevenue GrowthNet ProfitProfit Growth
FY 2024-25389
33.94% Profit
205
129.74% Profit
FY 2023-24291
473.02% Profit
89
715.58% Profit
FY 2022-2351
0% Profit
11
107.81% Profit

KRYS Similar Stocks

Stock NamePriceChange %VolumeMarket Cap ($Mn)PE Ratio
Vertex Pharmaceuticals

V

Vertex Pharmaceuticals

$520.66
-2.94%loss
610 1,32,00734.66
British American Tobacco

B

British American Tobacco

$57.47
-1.76%loss
13,143 1,23,76515.86
Regeneron Pharmaceuticals

R

Regeneron Pharmaceuticals

$922.40
-2.45%loss
179 93,74421.12
Moderna

M

Moderna

$199.33
+1.29%profit
24,095 80,653-
Argen X SE - ADR

A

Argen X SE - ADR

$942.04
+0.08%profit
3,598 59,24133.25

Invest in US Stocks with Dhan

Start building a global portfolio from just $1.

4.5 ratings

4.0 ratings

Dhan US Stocks App

Explore  |  Sitemap

*All securities mentioned on this website are exemplary and not recommendatory.

*Current prices on the website are delayed by 15 mins, login to check live prices.

We are bullish on India, we are bullish on India's prospects to be one of the largest economies in the world. We believe that the stock market provides a unique opportunity for all of India's traders and investors to participate in the growth story of the country.

Yet, most investing & trading platforms in India have remained more or less the same over the past decade. Times have changed and retail traders and investors have become smarter about managing their trades and money. Modern traders & investors require an online trading platform that helps them keep up with the technological advancements of our time.

That's why we're building Dhan - to help you trade, to help you invest, and to help you participate in India's growth stock via the stock market with awesome features and an incredible experience.

©2021-2026 Raise Securities Private Limited (formerly Moneylicious Securities Private Limited). All rights reserved. CIN: U74999MH2012PTC433549 Raise Securities is part of Raise Financial Services and works closely with Raise Partners across services.

SEBI Stock Broker Registration No: INZ000006031 | Depository Participant (CDSL) ID: IN-DP-289-2016 | SEBI Research Analyst Registration No: INH000023357
Exchange Membership No. : NSE: 90133 | BSE: 6593 | MCX: 56320
Registered & Corporate Office: Unit No. 2201, 22nd Floor, Gold Medal Avenue, S.V. Road, Beside Patel Petrol Pump, Piramal Nagar, Goregaon West, Mumbai – 400104, Customer Care: 9987761000.


For any query / feedback / clarifications, email at help@dhan.co.

In case of grievances for any of the services rendered by Raise Securities Private Limited, please write to grievance@dhan.co (for NSE, BSE and MCX) or grievancedp@dhan.co (for Depository Participant). Please ensure that you carefully read the Risk Disclosure Document as prescribed by SEBI, our Terms of Use and Privacy Policy. Compliance Officer: Mr. Manish Garg and Mobile: 8655740961 Email: complianceofficer@dhan.co To lodge your complaints using SEBI SCORES, click here.


Disclaimer: All communications with the client via chat, phone, or email are for support purposes only. Any commitments or statements made by the agent (human or virtual) shall not be binding on the company.


DHAN is a brand owned by Raise Securities Private Limited. All DHAN clients are registered under Raise Securities Private Limited. Clients are advised to refer to our company as Raise Securities Private Limited when communicating with regulatory authorities.


Procedure to file a complaint on SEBI SCORES/SMART ODR Portal: Register on SCORES portal. Mandatory details for filing complaints on SCORES: Name, PAN, Address, Mobile Number, E-mail ID. Benefits: Effective Communication, Speedy redressal of the grievances. You may refer the website https://scores.sebi.gov.in/ for more information. You may also download the SEBI Scores app to log a complaint Android: https://play.google.com›store›apps›sebiscores iOS: https://apps.apple.com›app›sebiscores.


Disclaimer: Investment in the securities market are subject to market risks, read all the related documents carefully before investing. Brokerage will not exceed the SEBI prescribed limit


Attention investors:

  1. Stock brokers can accept securities as margins from clients only by way of pledge in the depository system w.e.f September 01, 2020.
  2. Update your e-mail and phone number with your stock broker / depository participant and receive OTP directly from depository on your e-mail and/or mobile number to create pledge.
  3. Check your securities / MF / bonds in the consolidated account statement issued by NSDL/CDSL every month.

SEBI presents Samajh Se Investing Simple:

  • Understand Before You Invest
  • Choose Regulated Investment Products
  • Start Early, Stay Invested
  • Beware of Investment Frauds

Reporting of Short Sell Transactions by Clients:

Clients must report any short sale transaction, by emailing help@dhan.co with the subject “Reporting of Short Sell” on the same day.


Note: As a policy we do not give stock tips or recommendations and have not authorized anyone to give this on behalf of us. If you know anyone claiming to be a part of Dhan / / Raise or our associate companies or partners and offering such services, please report us on help@dhan.co. Important Information for Investors: To prevent unauthorized transactions in your trading / demat account, do not share your account details, credentials or any personal details with anyone. Keep your mobile number updated with your Stock Broker, Depository Participant and ensure that the same is registered with Stock Exchanges, Depository and KRAs. You will receive alerts and information on your registered mobile number / email for debit and other important transactions in your demat account directly from CDSL / Exchange on the same day. KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (Stock Broker, DP, Mutual Fund, etc.), you need not undergo the same process again when you approach another intermediary. No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account. This is issued in the interest of investors.


Investors should be cautious on unsolicited emails and SMS advising to buy, sell or hold securities and trade only on the basis of informed decision. Investors are advised to invest after conducting appropriate analysis of respective companies and not to blindly follow unfounded rumours, tips etc. Further, you are also requested to share your knowledge or evidence of systemic wrongdoing, potential frauds or unethical behaviour through the anonymous portal facility provided on BSE & NSE website. Issued in the interest of the investors.


Raise Securities Private Limited also known as Dhan is only an order collection platform that collects orders on behalf of clients and places them on BSE StarMF for execution. Client expressly agrees that Dhan is not liable or responsible and does not represent or warrant any damages regarding non- execution of orders or any incorrect execution of orders with regard to the funds chosen by the client or due to, but not being limited to, any link/system failure, delay in transfer of the funds on account of any unforeseen circumstances/issues in the banking system/payment aggregators or any other problems that may result in a delay in crediting the funds into the BSE Star MF's bank account. Raise Securities Private Limited (Dhan) does not engage in proprietary trading on its own account.


Mutual fund investments are subject to market risks, read all scheme related documents carefully before investing. Dhan is just acting as a distributor of Mutual Fund. Mutual Funds are not exchange-traded products. Any related disputes will not have access to the Exchange-investor redressal forum or arbitration mechanism. For other disclaimers please refer https://dhan.co/advertisement-disclaimer/


Download client registration documents (Rights & Obligations, Risk Disclosure Document, Do's & Don'ts) in vernacular language: BSE | NSE | MCX


Kindly, read the Advisory Guidelines of BSE | NSE | MCX for investors as prescribed by the exchange with reference to their circular dated 27th August, 2021 regarding investor awareness and safeguarding client's assets


Important Links: SEBI | BSE | NSE | MCX | CDSL | SCORES | ODR Portal | Investor Charter for Stock Brokers | Investor Charter for DP | Investor Charter for Research Analyst | UCC Advisory | e-Voting for Shareholders | NCL Client Collateral details | MCXCCL Client Collateral details

Important Information: Terms of Usage | Disclaimers | Privacy Policy | Grievances | Grievances RA | Risk Management Policy | Risk Disclosure | Advertisement Disclaimer | Referral Terms & Conditions | Saarthi 2.0 Mobile App for Investors | Master Circular for Online Dispute Resolution | Project Jagrook by SEBI